KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Change in Cash (2016 - 2025)

NovoCure (NVCR) has disclosed Change in Cash for 12 consecutive years, with -$241.2 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 944.14% to -$241.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$62.7 million through Dec 2025, up 18.0% year-over-year, with the annual reading at -$62.7 million for FY2025, 18.0% up from the prior year.
  • Change in Cash hit -$241.2 million in Q4 2025 for NovoCure, down from $192.5 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $330.1 million in Q3 2021 to a low of -$481.1 million in Q4 2021.
  • Historically, Change in Cash has averaged -$7.1 million across 5 years, with a median of $9.9 million in 2023.
  • Biggest YoY gain for Change in Cash was 2326.39% in 2021; the steepest drop was 4557.77% in 2021.
  • Year by year, Change in Cash stood at -$481.1 million in 2021, then surged by 73.35% to -$128.2 million in 2022, then surged by 167.12% to $86.1 million in 2023, then plummeted by 126.85% to -$23.1 million in 2024, then tumbled by 944.14% to -$241.2 million in 2025.
  • Business Quant data shows Change in Cash for NVCR at -$241.2 million in Q4 2025, $192.5 million in Q3 2025, and $22.7 million in Q2 2025.